A Novel Imaging System Distinguishes Neoplastic from Normal Tissue During Resection of Soft Tissue Sarcomas and Mast Cell Tumors in Dogs.
OBJECTIVE
To assess the ability of a novel imaging system designed for intraoperative detection of residual cancer in tumor beds to distinguish neoplastic from normal tissue in dogs undergoing resection of soft tissue sarcoma (STS) and mast cell tumor (MCT).


METHODS
Non-randomized prospective clinical trial.


METHODS
12 dogs with STS and 7 dogs with MCT.


METHODS
A fluorescent imaging agent that is activated by proteases in vivo was administered to the dogs 4-6 or 24-26 hours before tumor resection. During surgery, a handheld imaging device was used to measure fluorescence intensity within the cancerous portion of the resected specimen and determine an intensity threshold for subsequent identification of cancer. Selected areas within the resected specimen and tumor bed were then imaged, and biopsies (n=101) were obtained from areas that did or did not have a fluorescence intensity exceeding the threshold. Results of intraoperative fluorescence and histology were compared.


RESULTS
The imaging system correctly distinguished cancer from normal tissue in 93/101 biopsies (92%). Using histology as the reference, the sensitivity and specificity of the imaging system for identification of cancer in biopsies were 92% and 92%, respectively. There were 10/19 (53%) dogs which exhibited transient facial erythema soon after injection of the imaging agent which responded to but was not consistently prevented by intravenous diphenhydramine.


CONCLUSIONS
A fluorescence-based imaging system designed for intraoperative use can distinguish canine soft tissue sarcoma (STS) and mast cell tumor (MCT) tissue from normal tissue with a high degree of accuracy. The system has potential to assist surgeons in assessing the adequacy of tumor resections during surgery, potentially reducing the risk of local tumor recurrence. Although responsive to antihistamines, the risk of hypersensitivity needs to be considered in light of the potential benefits of this imaging system in dogs.
Duke University Medical Center, Durham, North Carolina.
Suzanne
S
Bartholf DeWitt
Duke University Medical Center, Durham, North Carolina.
William C
WC
Eward
Veterinary Specialty Hospital of the Carolinas, Cary, North Carolina.
Cindy A
CA
Eward
Duke University Medical Center, Durham, North Carolina.
Alexander L
AL
Lazarides
Duke University Medical Center, Durham, North Carolina.
Melodi Javid
MJ
Whitley
Lumicell, Inc., Wellesley, Massachusetts.
Jorge M
JM
Ferrer
Duke University Medical Center, Durham, North Carolina.
Brian E
BE
Brigman
Duke University Medical Center, Durham, North Carolina.
David G
DG
Kirsch
Cummings School of Veterinary Medicine, Tufts University, North Grafton, Massachusetts.
John
J
Berg
D000818:Animals; D001706:Biopsy; D004283:Dog Diseases / Q000000981:diagnostic imaging* / Q000601:surgery; D004285:Dogs; D005260:Female; D034801:Mastocytoma / Q000000981:diagnostic imaging / Q000601:surgery / Q000662:veterinary*; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control / Q000662:veterinary; D018365:Neoplasm, Residual; D011446:Prospective Studies; D012509:Sarcoma / Q000000981:diagnostic imaging / Q000473:pathology / Q000601:surgery / Q000662:veterinary*